JC Nickel, C Roehrborn, F Montorsi… - The Journal of …, 2011 - ncbi.nlm.nih.gov PURPOSE: Men at risk for prostate cancer may concurrently experience chronic prostatitis or pelvic pain. We evaluated the effect of dutasteride on prostatitis-like symptoms in the REDUCE study population. MATERIALS AND METHODS: REDUCE was a 4-year, randomized, ...
DA Shoskes, D Prots, J Karns, J Horhn… - The Journal of Urology, 2011 - Elsevier Age was similar in the chronic prostatitis/chronic pelvic pain syndrome group (range 22 to 63 years, median 40) and controls (range 19 to 57, median 40). Patients had median symptom duration of 24 months (range 3 to 440), a mean Chronic Prostatitis Symptom Index score of 24.7 ± ...
MK Samplaski, J Li… - Urology, 2011 - Elsevier To evaluate the addition of an erectile dysfunction (ED) domain to the UPOINT (Urinary, Psychosocial, Organ-specific, Infection, Neurologic/systemic, and Tenderness) system in our patients. The UPOINT system classifies men with chronic prostatitis/chronic pelvic pain ... Related articles - All 3 versions
DA Shoskes… - Urologic Clinics of North America, 2011 - Elsevier Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a common condition with a heterogeneous origin that responds best to multimodal therapy. The bioflavonoid quercetin has antioxidant and antiinflammatory effects that have proven useful for treating this condition. Using the ...
JC Nickel, MP O'Leary, H Lepor, KE Caramelli… - The Journal of …, 2011 - Elsevier Of 151 patients (mean age 48 years) 52 received 4 mg silodosin, 45 received 8 mg silodosin and 54 received placebo. Silodosin 4 mg was associated with a significant decrease in total National Institutes of Health Chronic Prostatitis Symptom Index score (mean ± SD change ... Cited by 1 - Related articles - All 5 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
